Structure and Function of the CaaX Protease Ste24p

CaaX 蛋白酶 Ste24p 的结构和功能

基本信息

  • 批准号:
    8898849
  • 负责人:
  • 金额:
    $ 39.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-01 至 2018-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Post-translational lipidation provides critical modulation of the functions of some proteins. Isoprenoids (i.e., farnesyl or geranylgeranyl groups) are attached to cysteine residues in proteins containing C-terminal CaaX sequence motifs. Isoprenylation is generally accompanied by two subsequent processing steps, proteolytic cleavage of the aaX residues and carboxymethylation of the newly exposed carbonyl group of the modified cysteine residue. Some isoprenylated proteins also undergo additional proteolytic processing, including an additional cleavage by the same protease that initially removes the aaX residues. As substrates for CaaX processing include ras and rho, small GTPases frequently mutated in cancers, the enzymes of the CaaX pathway are validated targets for cancer drug discovery. Due to its role in maturation of the a-factor mating pheromone, the first-identified and best-characterized CaaX protease is the yeast zinc metalloprotease Ste24p. A human ortholog of Ste24p, ZMPSTE24, can complement the full function of yeast Ste24p. The only known substrate for the human protein is prelamin A, the precursor to the nuclear intermediate filament protein lamin A. Mutations in either ZMPSTE24 or the processing site of prelamin A are associated with a spectrum of premature-aging diseases referred to as progeria. Also, ZMPSTE24 is inhibited by antiviral drugs designed to target the HIV aspartyl protease, and this off-target effect may give rise to some of the severe side-effects of these drugs. We determined the crystal structure of yeast Ste24p. Its core structure is a ring of seven transmembrane helices enclosing a large (14,000 Å3) interior volume (CAVITY) that contains the active-site and substrate binding region (GROOVE). The cavity is accessible to the external milieu via gaps (PORTALS), partially occluded by non-transmembrane domains, that are between pairs of splayed transmembrane helices. Human ZMPSTE24, solved contemporaneously by another group, possesses the same architecture. The structures of yeast Ste24p and human ZMPSTE24 are quite similar, with a pairwise RMSD of ~1.2 Å. We propose that cleavage proceeds via a processive processing mechanism (PPM) of substrate insertion, translocation and ejection. The role of the large cavity, the mechanism of specific recognition of cleavage sites with divergent sequences, the unusual dual cleavage process, and the role of the farnesyl group in recognition are some of the questions we seek to address with this research proposal that features structure-function studies of the yeast and human enzymes.
描述(由申请方提供):翻译后脂化提供了某些蛋白质功能的关键调节。类异戊二烯(即,法呢基或香叶基香叶基)连接到含有C-末端CaaX序列基序的蛋白质中的半胱氨酸残基上。异戊二烯化通常伴随两个后续加工步骤,aaX残基的蛋白水解裂解和修饰的半胱氨酸残基的新暴露的羰基的羧甲基化。一些异戊二烯化的蛋白质还经历另外的蛋白水解加工,包括由最初去除aaX残基的相同蛋白酶进行的另外的切割。由于CaaX加工的底物包括ras和rho,即在癌症中经常突变的小GTP酶,因此CaaX途径的酶是癌症药物发现的经验证的靶标。由于其在a因子交配信息素成熟中的作用, 最佳表征的CaaX蛋白酶是酵母锌金属蛋白酶Ste 24 p。Ste 24 p的人类直系同源物ZMPSTE 24可以补充酵母Ste 24 p的全部功能。人类蛋白质的唯一已知底物是前核纤层蛋白A,核中间丝蛋白核纤层蛋白A的前体。ZMPSTE 24或前层蛋白A加工位点的突变与一系列称为早衰症的早衰性疾病相关。此外,ZMPSTE 24会被旨在靶向HIV天冬氨酰蛋白酶的抗病毒药物抑制,这种脱靶效应可能会导致这些药物的一些严重副作用。我们测定了酵母Ste 24 p的晶体结构。它的核心结构是一个由7个跨膜螺旋组成的环,包围着一个包含活性位点和底物结合区(GROOVE)的大(14,000 μ 3)内部体积(CAVITY)。腔可经由间隙(门户)进入外部环境,所述间隙部分地被非跨膜结构域封闭,所述非跨膜结构域在成对的张开的跨膜螺旋之间。人类ZMPSTE 24,由另一个小组同时解决,具有相同的结构。酵母Ste 24 p和人ZMPSTE 24的结构非常相似,成对RMSD为~1.2 μ g。我们建议,裂解收益通过基板插入,易位和弹出的过程处理机制(PPM)。大空腔的作用、具有不同序列的切割位点的特异性识别机制、不寻常的双重切割过程以及法尼基基团在识别中的作用是我们试图通过这项研究提案解决的一些问题,该研究提案的特点是酵母和人类酶的结构-功能研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael Wiener其他文献

Michael Wiener的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael Wiener', 18)}}的其他基金

Structure and Function of the CaaX Protease Ste24p
CaaX 蛋白酶 Ste24p 的结构和功能
  • 批准号:
    8610715
  • 财政年份:
    2014
  • 资助金额:
    $ 39.16万
  • 项目类别:
Structure and Function of the CaaX Protease Ste24p
CaaX 蛋白酶 Ste24p 的结构和功能
  • 批准号:
    9059738
  • 财政年份:
    2014
  • 资助金额:
    $ 39.16万
  • 项目类别:
Multi-level optimization of membrane proteins for crystallography
用于晶体学的膜蛋白的多级优化
  • 批准号:
    8152523
  • 财政年份:
    2010
  • 资助金额:
    $ 39.16万
  • 项目类别:
Structural Biology of Cancer Related Membrane Proteins Expressed in P. Pastoris
毕赤酵母表达的癌症相关膜蛋白的结构生物学
  • 批准号:
    7489827
  • 财政年份:
    2007
  • 资助金额:
    $ 39.16万
  • 项目类别:
Structural Biology of Cancer Related Membrane Proteins Expressed in P. Pastoris
毕赤酵母表达的癌症相关膜蛋白的结构生物学
  • 批准号:
    7683733
  • 财政年份:
    2007
  • 资助金额:
    $ 39.16万
  • 项目类别:
Structural Biology of Cancer Related Membrane Proteins Expressed in P. Pastoris
毕赤酵母表达的癌症相关膜蛋白的结构生物学
  • 批准号:
    7313169
  • 财政年份:
    2007
  • 资助金额:
    $ 39.16万
  • 项目类别:
Improved Methods for Membrane Protein Crystallization
膜蛋白结晶的改进方法
  • 批准号:
    7123041
  • 财政年份:
    2005
  • 资助金额:
    $ 39.16万
  • 项目类别:
Improved Methods for Membrane Protein Crystallization(RMI)
膜蛋白结晶 (RMI) 的改进方法
  • 批准号:
    7265251
  • 财政年份:
    2005
  • 资助金额:
    $ 39.16万
  • 项目类别:
Improved Methods: Membrane Protein Crystallization(RMI)
改进方法:膜蛋白结晶(RMI)
  • 批准号:
    7012589
  • 财政年份:
    2005
  • 资助金额:
    $ 39.16万
  • 项目类别:
PERIPHERAL BENZODIAZEPINE RECEPTOR STRUCTURAL BIOLOGY
外周苯二氮卓受体结构生物学
  • 批准号:
    6851390
  • 财政年份:
    2005
  • 资助金额:
    $ 39.16万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.16万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了